TY - JOUR
T1 - The use of immunomodulators in the control of infectious bovine rhinotracheitis
AU - Castrucci, G.
AU - Osburn, Bennie
AU - Frigeri, F.
AU - Ferrari, M.
AU - Salvatori, D.
AU - Lo Dico, M.
AU - Barreca, F.
PY - 2000/7/1
Y1 - 2000/7/1
N2 - Three experiments have been carried out to verify the effectiveness of an immunomodulator, Baypamun (Bayer AG) in limiting the spread of Bovine herpesvirus-1 (BHV-1), the causal agent of infectious bovine rhinotracheitis (IBR). In the first experiment, four calves infected with BHV-1 developed severe disease whereas four calves given Baypamun simultaneously with the virus had less severe disease. Four other calves in contact with the infected calves became severely ill but another four given Baypamun were only mildly affected. In the second experiment three calves infected with BHV-1, which reacted with typical disease, were allowed to remain in contact with six calves. All six calves were given Baypamun at various times following the exposure to BHV-1 infection and all showed a much reduced reaction with two treated for 4 days developing no clinical disease. Finally, in the third experiment one calf vaccinated one month before the start of the experiment did not develop any signs of disease when housed together with a calf experimentally infected with BHV-1. Of four other calves, vaccinated when the infected calf showed the first signs of disease, only the two given Baypamun in addition to the vaccine, were protected from clinical disease whereas the two given vaccine only developed classical sign of IBR. In the three experiments the virus shadding by the Baypamun-treated calves resulted to be significantly reduced. (C) 2000 Elsevier Science Ltd. All rights reserved.
AB - Three experiments have been carried out to verify the effectiveness of an immunomodulator, Baypamun (Bayer AG) in limiting the spread of Bovine herpesvirus-1 (BHV-1), the causal agent of infectious bovine rhinotracheitis (IBR). In the first experiment, four calves infected with BHV-1 developed severe disease whereas four calves given Baypamun simultaneously with the virus had less severe disease. Four other calves in contact with the infected calves became severely ill but another four given Baypamun were only mildly affected. In the second experiment three calves infected with BHV-1, which reacted with typical disease, were allowed to remain in contact with six calves. All six calves were given Baypamun at various times following the exposure to BHV-1 infection and all showed a much reduced reaction with two treated for 4 days developing no clinical disease. Finally, in the third experiment one calf vaccinated one month before the start of the experiment did not develop any signs of disease when housed together with a calf experimentally infected with BHV-1. Of four other calves, vaccinated when the infected calf showed the first signs of disease, only the two given Baypamun in addition to the vaccine, were protected from clinical disease whereas the two given vaccine only developed classical sign of IBR. In the three experiments the virus shadding by the Baypamun-treated calves resulted to be significantly reduced. (C) 2000 Elsevier Science Ltd. All rights reserved.
KW - Calves
KW - Immunomodulators
KW - Infectious bovine rhinotracheitis
UR - http://www.scopus.com/inward/record.url?scp=0034124605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034124605&partnerID=8YFLogxK
U2 - 10.1016/S0147-9571(99)00069-7
DO - 10.1016/S0147-9571(99)00069-7
M3 - Article
C2 - 10855662
AN - SCOPUS:0034124605
VL - 23
SP - 163
EP - 173
JO - Comparative Immunology, Microbiology and Infectious Diseases
JF - Comparative Immunology, Microbiology and Infectious Diseases
SN - 0147-9571
IS - 3
ER -